Entropin Names Bruce R. Manning to Board of Directors.Business Editors & Health/Medical Writers INDIO, Calif.--(BW HealthWire)--July 10, 2001 Entropin Inc. (Nasdaq:ETOP ETOP Engineering Turnover Package ETOP Expedited Task Order Process ) (Nasdaq:ETOPW), a specialty pharmaceutical company developing new therapeutics for painful soft tissue injuries and diseases, today announced the appointment of Bruce R. Manning, R.Ph., age 58, to the Entropin Board of Directors, bringing the total number of directors to seven. Manning has 35 years' experience in planning regulatory strategy, in preparing regulatory submissions and in negotiating at all levels of the U.S Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ). He also spent 10 years as a line manager with overall responsibility for the development of drug products at a U.S. subsidiary of a multinational pharmaceutical company. He is a registered pharmacist with a B.S. in pharmacy from the Massachusetts College of Pharmacy A college of pharmacy generally refers to a tertiary educational institution (or part of such an institution) which is involved in the education of future pharmacists and pharmaconomists. in Boston. "Bruce is a strong addition to our board of directors," said Higgins D. Bailey, Ed.D., Entropin's chairman. "His expertise in product development and regulatory affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: Manning is the president of New England New England, name applied to the region comprising six states of the NE United States—Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, and Connecticut. The region is thought to have been so named by Capt. Biomedical Research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. Inc. (NEBR NEBR Nebraska (old style) NEBR Nuclear Emergency Briefing Room (United Kingdom) NEBR New England Build and Restore, Inc. ), a consulting firm Noun 1. consulting firm - a firm of experts providing professional advice to an organization for a fee consulting company business firm, firm, house - the members of a business organization that owns or operates one or more establishments; "he worked for a organized to provide regulatory affairs and product development services to the pharmaceutical, medical device and biotechnology industries. Prior to founding NEBR in 1990, he was vice president of regulatory affairs and product development for Astra Pharmaceutical Products. During his 20-year career with Astra, he developed and obtained regulatory approval for more than 150 medical products. Manning's extensive experience with the FDA began early in his career when he was employed by the agency as a reviewer. Commenting on his board appointment, Manning said: "I am looking forward to serving as a director of Entropin. Esterom(R) is a unique product, and I am enthusiastic about its potential and the future success of the company." About Entropin Entropin Inc. is a pharmaceutical research and development company, initially focused on the development of Esterom(R), a novel topical therapeutic for the treatment of painful soft tissue injuries, such as tendonitis tendonitis /ten·do·ni·tis/ (ten?do-ni´tis) tendinitis. ten·do·ni·tis n. Variant of tendinitis. or back sprain sprain, stretching or wrenching of the ligaments and tendons of a joint, often with rupture of the tissues but without dislocation. Sprains occur most commonly at the ankle, knee, or wrist joints, causing pain, swelling, and difficulty in moving the involved joint. , that result in impaired function. This news release includes forward-looking statements that reflect Entropin's current views with respect to future events and financial performance. The words "believe," "expect," "anticipate," and similar expressions identify forward-looking statements. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: (1) the ability to successfully complete development and commercialization of products, including the cost, scope and results of pre-clinical and clinical testing; (2) the ability to successfully complete product research and further development, including pre-clinical and clinical studies; (3) the time, cost and uncertainty of obtaining regulatory approvals; (4) the ability to obtain substantial additional funding; (5) the ability to develop and commercialize products before competitors; and (6) other factors detailed from time to time in filings with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion